Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 282.00
Bid: 284.00
Ask: 288.00
Change: 2.00 (0.71%)
Spread: 4.00 (1.408%)
Open: 278.00
High: 286.00
Low: 278.00
Prev. Close: 280.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks down as aggressive US Fed rate hike looms

Tue, 03rd May 2022 12:14

(Alliance News) - Stock prices in London were lower at midday on Tuesday following the long bank holiday weekend in the UK, as markets globally prepare for a sharp US interest rate hike and similar moves by other central banks as they struggle to control inflation.

All eyes are on the conclusion on Wednesday of the Federal Reserve's two-day policy meeting, where it is expected to lift borrowing costs by half a percentage point. It would be the first time since 2000 that the US central bank has raised rates by 50 basis points at one meeting.

Earlier Tuesday, Australia joined the tightened cycle started by central banks elsewhere. The Sydney-based central bank raised the main lending rate by 25 basis points to 0.35%, the first increase since November 2010.

The FTSE 100 index was down 32.64 points, or 0.4%, at 7,511.91. The mid-cap FTSE 250 index was down 12.02 points, or 0.1%, at 20,696.69. The AIM All-Share index was down 2.31 points, or 0.1%, at 1,019.95.

The Cboe UK 100 index was down 0.7% at 745.25. The Cboe 250 was down 0.5% at 18,172.69. The Cboe Small Companies climbed 0.1% to 15,174.74.

In mainland Europe, the CAC 40 in Paris was up 0.2% and the DAX 40 in Frankfurt was up 0.4%.

"Markets are particularly worried about lockdown in China and how fast US interest rates might go up. We'll get clarity on the latter tomorrow when the Federal Reserve gives its latest policy decision, with markets expecting half a percentage point increase in the Fed Funds rate. Central banks typically raise rates by a quarter percentage point, but the Fed is under pressure to be more aggressive to combat rising inflation," said AJ Bell's Russ Mould.

The Bank of England will announce its own rate decision on Thursday.

"Can the BoE surprise with a 50bps hike at some point this year? The short answer: it's a long shot," commented Sanjay Raja, senior economist at Deutsche Bank. "While a bigger move may be on the table in the coming meetings, we see...reasons why a 50bps move remains unlikely in the UK, despite other central banks upping the ante for bigger moves."

Raja noted that the UK central bank moved early, so it doesn't need to catch-up with global peers. As well, more so than other advanced economies, the UK is at risk of falling into recession.

In the FTSE 100, M&G was up 3.0% at midday on Tuesday, after HSBC raised the investment manager to 'buy' from 'hold'.

In addition, St James's Place was up 1.9% after HSBC also upgraded the wealth manager to 'buy' from 'hold'.

BP was up 2.0%. The oil major swung to a first-quarter loss due to its decision to exit from its shareholding in Rosneft in response to Moscow's invasion of Ukraine; however on an underlying basis, the oil major reported a big jump in profit.

For the three months that ended March 31, BP swung to an attributable loss of USD20.38 billion from a USD4.67 billion profit in the first quarter last year. BP said the reported result included pretax adjusted items of USD30.8 billion.

By its preferred metric, BP swung to a replacement cost loss of USD23.04 billion from a replacement cost profit of USD3.33 billion the year before.

The London-based firm attributed the loss to its decision to exit its near-20% shareholding in state-owned Russian oil firm Rosneft. BP said that, in the first quarter, the total post-tax charge for this was USD25.5 billion.

On an underlying replacement cost basis, BP reported a profit of USD6.25 billion, up 54% from USD4.07 billion in the fourth quarter of last year and more than doubled from USD2.63 billion a year ago.

BP raised its first-quarter dividend by 4.0% to 5.46 cents from 5.25 cents the year before. Further, during the first quarter BP generated surplus cash flow of USD4.1 billion and said it intends to execute a USD2.5 billion share buyback prior to announcing its second quarter results.

Rival oil producer Shell, which posts its own first-quarter numbers on Thursday, was down 1.0%.

BP's results come as calls from the opposition Labour Party for a windfall tax on UK oil majors grow louder, as the country grapples with a cost-of-living crisis.

Last week, UK Chancellor of the Exchequer Rishi Sunak appeared to distance himself from such a tax but did not entirely rule it out.

The chancellor called on companies making generating large profit to invest the cash back into the UK instead.

"It sounds appealing. 'Great, we're taxing bad energy companies more, that will solve all our problems'," he said in an interview with Mumsnet. "The reason we haven't gone down that road is, really simply…we need to invest more. That's why we haven't gone for some extra tax. Because what I don't want to do is discourage investment in our own energy supplies."

The view was echoed by UK Prime Minister Boris Johnson who said on Tuesday that a windfall tax on big energy firms would deter investment and make it harder to meet the country's net-zero environmental goals.

At the other end of the large-caps, Segro was the worst performer, down 7.4%. Kepler Cheuvreux downgraded the warehouse property investor to 'hold' from 'reduce'.

In the FTSE 250, Auction Technology Group was the best performer, up 7.0%, after JPMorgan raised the online auction operator to 'overweight' from 'neutral'.

Energean was up 4.5%. Subsidiary Energean Israel signed a gas sales agreement with the East Hagit Power Plant Ltd Partnership.

Under the agreement, Energean will supply gas to East Hagit for a term of 15 years, with a total contract quantity of up to 12 billion cubic feet. Energean said the agreement has the potential to generate revenue of up to USD2 billion over the offtake period.

On AIM, Hutchmed (China) was down 15%, after the drugmaker said the US Food & Drug Administration has rejected its surufatinib for treatment of pancreatic neuroendocrine tumours.

In a complete response letter, the FDA said the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time".

The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively.

The dollar was higher across the board as the US Federal Reserve's two-day policy meeting gets underway. The pound was quoted at USD1.2512 at midday on Tuesday, down from USD1.2568 at the London equities close Friday.

The euro was priced at USD1.0517, down from USD1.0547. Against the Japanese yen, the dollar was trading at JPY130.11, up from JPY129.68.

On the economic front, UK manufacturing sector activity edged higher last month on increased intakes of new business against a backdrop of rising price inflationary pressures, S&P Global said.

The UK S&P Global-CIPS manufacturing purchasing managers' index was 55.8 points in April, up slightly from the preliminary estimate of 55.3 and the score of 55.2 registered in March.

S&P said the start of the second quarter saw a mild growth acceleration in the UK manufacturing sector. The rate of expansion in output improved from March's five-month low, leading to a further solid increase in staffing levels.

Brent oil was quoted at USD106.51 a barrel on Tuesday at midday, down sharply from USD110.30 at the London equities close on Friday. Gold stood at USD1,858.33 an ounce, down from USD1,906.75.

New York was pointed to a slightly lower open ahead of earnings reports from semiconductor maker Advanced Micro Devices, drugmaker Pfizer, and coffee-house chain Starbucks.

The Dow Jones Industrial Average was called down 0.2%, the S&P 500 down 0.1%, and the Nasdaq Composite down 0.3%, based on futures trading. The stock indices had closed up 0.3%, 0.6% and 1.6% respectively on Monday.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
14 Jun 2019 14:40

Hutchison Chi-Med makes progress with surufatinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee (IDMC) of the phase 3 pivotal study of 'surufatinib' in advanced neuroendocrine tumors - extra-pancreatic (SANET-ep) had completed a planned interim analysis.

Read more
29 May 2019 12:38

Hutchison China Meditech Shareholders Approve Subdivision Of Shares (ALLISS)

LONDON (Alliance News) - Hutchison China Meditech Ltd on Wednesday said its shareholders have approved a subdivision of shares at its extraordinary general meeting.The pharmaceutical that a

Read more
17 Apr 2019 16:02

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 18 AprilDomino's Pizza GroupSEGRORPC Group (re acquisition by Berry 19 events 22 events 23

Read more
3 Apr 2019 12:58

Gama Aviation Appoints Managing Director Of Major Shareholder As Chair

LONDON (Alliance News) - Gama Aviation PLC on Wednesday said it has selected the managing director of major shareholder Hutchison Whampoa China Ltd as its new chair.Shares in business firm

Read more
29 Mar 2019 09:16

Hutchison China MediTech Surufatinib Cancer Study Doses First Patient

LONDON (Alliance News) - Biopharmaceutical firm Hutchison China MediTech Ltd on Friday said it has begun a study of cancer drug surufatinib in patients with advanced biliary tract biliary tract by

Read more
11 Mar 2019 11:54

Hutchison loss widens as China legislation hampers revenue

(Sharecast News) - Hutchison China Meditech on Monday reported a drop in sales and increased annual loss after the implementation of new government policy in China.

Read more
11 Mar 2019 08:45

Hutchison China Meditech 2018 Loss Widens On New Government Policy

LONDON (Alliance News) - Hutchison China Meditech Ltd on Monday said its loss widened in 2018 as sales decreased following an implementation of new government policy in China.The company to

Read more
29 Nov 2018 12:17

Hutchison Chi-Med enters four new drug test collaborations

(Sharecast News) - Hutchison China MediTech, doing business as Chi-Med, has entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of its 'surufatinib' (HMPL-012 or sulfatinib) and 'fruquintinib' products, in combination with checkpoint inhibitors.

Read more
26 Nov 2018 08:35

Hutchison China Meditech Starts Fruquintinib Capsules Sales In China

LONDON (Alliance News) - Hutchison China Meditech Ltd on Monday said it launched fruquintinib capsules Elunate with the initiation of product sales in China.Elunate is used for the of with

Read more
19 Nov 2018 19:02

SVM UK Emerging Fund Beats Benchmark With Three Key Holdings

LONDON (Alliance News) - SVM UK Emerging Fund PLC on Monday said it had outpaced its benchmark in its most recent half year due to strong performances from three key holdings.As at 30, the

Read more
18 Oct 2018 10:09

Hutchison China Meditech Starts Phase I Study For Leukemia In China

LONDON (Alliance News) - Hutchison China Meditech Ltd said Thursday it commenced a phase I study of HMPL-523 to treat elderly patients with acute myeloid leukemia in China.The aim of the is

Read more
5 Sep 2018 08:28

Hutchison Gains Fruquintinib Capsules Approval As Cancer Drug In China

LONDON (Alliance News) - Hutchison China Meditech Ltd said Wednesday it gained Chinese approval for its Fruquintinib capsules to be used as treatment for metastatic colorectal cancer.The of

Read more
27 Jul 2018 08:54

Hutchinson China Meditech Swings To Net Loss, Ups Annual Loss Estimate

LONDON (Alliance News) - Hutchison China Meditech Ltd on Friday raised its annual loss estimate by USD20 million after swinging to an interim net loss.For the six months to June 30, the a a

Read more
20 Jul 2018 15:50

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 23 July Ryanair HoldingsQ1 ResultsAscentialHalf Year Retail GroupHalf 24

Read more
4 Jun 2018 11:11

Hutchison China Cancer Trial Shows Clinically Meaningful Benefits

LONDON (Alliance News) - Biopharmaceutical company Hutchison China MediTech Ltd said Monday patients in its FRESCO Phase III study "demonstrated a statistically significant and clinically at

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.